NIH-funded research R21 grant

Understanding muscle pain caused by breast cancer treatments

Official title: A Drosophila model for Aromatase Inhibitor-induced Musculoskeletal Pain

Funded at Icahn School of Medicine at Mount Sinai · NIH-11212285 · Data updated 2026-11-12

This study is looking at why some post-menopausal women with hormone receptor positive breast cancer experience painful side effects from their hormone treatments, and it hopes to find ways to help doctors choose the best treatment for each patient right from the start, making their experience easier and more comfortable.

More Musculoskeletal Pain research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionIcahn School of Medicine at Mount Sinai
NIH-funded
Lab location1 site (New York, United States)
Project startJune 10, 2025
Project endMay 31, 2027
Funding year2025
Award (this year)$434,542
NIH project number1R21CA303409-01
Project IDNIH-11212285 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are post-menopausal women diagnosed with hormone receptor positive breast cancer who are considering or currently undergoing treatment with Aromatase Inhibitors.

Less likely to help

Patients who are not post-menopausal or those with hormone receptor negative breast cancer may not benefit from this research.

What this research studies

This research investigates the painful side effects experienced by post-menopausal women taking Aromatase Inhibitors (AIs) for hormone receptor positive breast cancer. Using a Drosophila model, the study aims to identify genetic factors that contribute to musculoskeletal pain associated with these treatments. By understanding these genetic susceptibilities, the goal is to match patients with the most suitable AI from the start, potentially reducing the trial-and-error process that many endure. This approach could lead to improved quality of life for patients by minimizing painful side effects.

Why it matters

Potential benefit: If successful, this research could significantly enhance the quality of life for breast cancer patients by reducing treatment-related pain.

How similar studies have gone: While the use of genetic profiling to match patients with specific treatments is a growing field, this particular approach using a Drosophila model for AIs is relatively novel and has not been extensively tested.

Where this research is happening

  • Icahn School of Medicine at Mount Sinai
    New York, United States
    Active

Researchers

  • Principal investigator: Pfleger, Cathie M — Icahn School of Medicine at Mount Sinai
  • Study coordinator: Pfleger, Cathie M

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.